rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Heidy King-Jones

Officer

Company insider

Files Form 4 as: Officer, Spyre Therapeutics; Chief Legal Officer, Provention Bio; General Counsel, SVP Legal, Axcella Health.

Every Form 4 they filed

In numbers

Trades disclosed
42
Buys
0
Sells
3
Bought
$0
Sold
$7.6M
Companies
3
Companies where not an officer
0
First trade
18 Dec 2019
Last trade
1 Oct 2026
Last filed
2 Oct 2026

Companies traded

Where they are an officer
SYRE Spyre TherapeuticsOfficer · Biotechnology · last 1 Oct 20260 buys · 3 sells
Provention BioOfficer · last 27 Apr 20230 buys · 0 sells
Axcella HealthOfficer · last 18 Dec 20190 buys · 0 sells

Activity over time

1 Aug – 1 Oct
201 Aug1 Sep1 Oct

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
1 Oct 2026filed 2 Oct 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Code M$420K28,933 at $14.50filing
1 Oct 2026filed 2 Oct 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Sold$36K400 at $89.24filing
1 Oct 2026filed 2 Oct 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Sold$1.5M16,605 at $90.35filing
1 Oct 2026filed 2 Oct 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Sold$660K7,228 at $91.35filing
1 Oct 2026filed 2 Oct 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Sold$195K2,100 at $92.70filing
1 Oct 2026filed 2 Oct 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Sold$243K2,600 at $93.46filing
1 Oct 2026filed 2 Oct 2026SYRE Spyre Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—28,933 at $0.00filing
2 Sep 2026filed 3 Sep 2026SYRE Spyre Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—400 at $0.00filing
2 Sep 2026filed 3 Sep 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Code M$5,800400 at $14.50filing
2 Sep 2026filed 3 Sep 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Sold$36K400 at $90.00filing
2 Sep 2026filed 3 Sep 2026SYRE Spyre Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—400 at $0.00filing
2 Sep 2026filed 3 Sep 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Code M$5,800400 at $14.50filing
2 Sep 2026filed 3 Sep 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Sold$36K400 at $90.00filing
1 Sep 2026filed 3 Sep 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Code M$406K27,999 at $14.50filing
1 Sep 2026filed 3 Sep 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Sold$419K4,845 at $86.40filing
1 Sep 2026filed 3 Sep 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Sold$1.4M16,548 at $87.20filing
1 Sep 2026filed 3 Sep 2026SYRE Spyre Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—27,999 at $0.00filing
1 Sep 2026filed 3 Sep 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Sold$547K6,206 at $88.17filing
1 Sep 2026filed 3 Sep 2026SYRE Spyre TherapeuticsBiotechnologySEC FORM 4 Sold$36K400 at $89.38filing
1 Sep 2026filed 3 Sep 2026SYRE Spyre Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—27,999 at $0.00filing

Sectors

Health Care3

Buys in green, sells in red, by the company’s sector.

Related people

Cameron TurtleChief Executive Officer · Chief Executive Officer at Spyre Therapeutics, filing Form 4 there in the last year
Scott L. BurrowsChief Financial Officer · Chief Financial Officer at Spyre Therapeutics, filing Form 4 there in the last year
Jeffrey W. AlbersDirector · Director at Spyre Therapeutics, filing Form 4 there in the last year
Sheldon SloanChief Medical Officer · Chief Medical Officer at Spyre Therapeutics, filing Form 4 there in the last year
Michael Thomas HendersonChief Executive Officer · Director at Spyre Therapeutics, filing Form 4 there in the last year